Tyrosine kinase 2 inhibitor - Bristol-Myers SquibbAlternative Names: TYK2 inhibitor - Bristol-Myers Squibb
Latest Information Update: 09 Aug 2016
At a glance
- Originator Bristol-Myers Squibb
- Class Small molecules
- Mechanism of Action TYK2 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
Most Recent Events
- 01 May 2016 Phase-I clinical trials in Autoimmune disorders (unspecified route)